Edition:
United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

5.23USD
24 Jul 2017
Change (% chg)

$0.18 (+3.56%)
Prev Close
$5.05
Open
$5.06
Day's High
$5.27
Day's Low
$5.00
Volume
957,899
Avg. Vol
1,006,650
52-wk High
$7.49
52-wk Low
$3.20

Select another date:

Mon, Jun 5 2017

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

BRIEF-Agenus Q1 loss per share $0.18

* Agenus reports first quarter 2017 financial results and provides corporate update

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

* Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities

* Agenus restructures business to sharpen focus on clinical development of cancer therapies

BRIEF-Incyte and Agenus amend collaboration agreement

* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs

BRIEF-Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus

* Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing Source text - http://bit.ly/2lpg9SS Further company coverage:

BRIEF-QVT Financial reports 5.08 pct passive stake in Agenus

* QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing Source text - http://bit.ly/2jHW6OQ Further company coverage:

Select another date: